
MannKind Corporation: shareholders and insiders
Price
$4.07
November 18, 2026Market cap $1.3B
What Ploutos Investor adds for MannKind
Part of Ploutos Investor, €9.99 a month
- The full history: 16 fiscal years, from 2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
Insiders and their shares
Purchases and sales by officers and directors from Nov 19, 2025 to Sep 28, 2026, from their own Form 4 filings.
Bought on the market
$259.0K
1 person
Sold on the market
$3.2M
4 people
From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan100%
- The rest0%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $259.0K by 1 person·sold $1.1M by 3 people
- 2025: no buys, sold $2.1M by 2 people
- 2026: bought $259.0K by 1 person, sold $1.1M by 3 people
- Sep 25, 2026Steven B. BinderDirectorKind10b5-1
- Sep 10, 2026Steven B. BinderDirectorKind10b5-1
- Aug 7, 2026Steven B. BinderDirectorKind10b5-1
- Jul 17, 2026David ThomsonEVP Genl Counsel & SecretaryKind10b5-1
- Jul 17, 2026Steven B. BinderDirectorKind10b5-1
- Jul 15, 2026Christopher B PrentissChief Financial OfficerKind
- Jul 15, 2026Christopher B PrentissChief Financial OfficerKind
- Jul 15, 2026Dominic MarascoPres, Endocrine Business UnitKind
- Jul 15, 2026Stuart A TrossChief People & Workpl OfficerKind
- Jul 15, 2026Stuart A TrossChief People & Workpl OfficerKind
- Jul 15, 2026Stuart A TrossChief People & Workpl OfficerKind
- Jul 15, 2026Stuart A TrossChief People & Workpl OfficerKind
- Jul 15, 2026Stuart A TrossChief People & Workpl OfficerKind
- Jul 15, 2026Michael CastagnaChief Executive OfficerKind
- Jul 15, 2026Michael CastagnaChief Executive OfficerKind
- Jul 15, 2026Michael CastagnaChief Executive OfficerKind
- Jul 15, 2026Michael CastagnaChief Executive OfficerKind
- Jul 15, 2026Michael CastagnaChief Executive OfficerKind
- Jul 15, 2026Sanjay R SinghEVP Technical OperationsKind
- Jul 15, 2026Sanjay R SinghEVP Technical OperationsKind
- Jul 15, 2026Sanjay R SinghEVP Technical OperationsKind
- Jul 15, 2026Sanjay R SinghEVP Technical OperationsKind
- Jul 15, 2026Sanjay R SinghEVP Technical OperationsKind
- Jul 15, 2026David ThomsonEVP Genl Counsel & SecretaryKind10b5-1
- Jul 15, 2026David ThomsonEVP Genl Counsel & SecretaryKind10b5-1
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 25, 2026 | Steven B. BinderDirector | 10b5-1 | 39.1K | $3.29 | $128.5K | Form 4 |
| Sep 10, 2026 | Steven B. BinderDirector | 10b5-1 | 33.6K | $3.81 | $127.9K | Form 4 |
| Aug 7, 2026 | Steven B. BinderDirector | 10b5-1 | 39.1K | $4.06 | $158.5K | Form 4 |
| Jul 17, 2026 | David ThomsonEVP Genl Counsel & Secretary | 10b5-1 | 24.1K | $4.05 | $97.6K | Form 4 |
| Jul 17, 2026 | Steven B. BinderDirector | 10b5-1 | 52.5K | $4.06 | $213.1K | Form 4 |
| Jul 15, 2026 | Christopher B PrentissChief Financial Officer | 11.6K | $4.09 | $47.3K | Form 4 | |
| Jul 15, 2026 | Christopher B PrentissChief Financial Officer | 10.7K | $4.09 | $43.7K | Form 4 | |
| Jul 15, 2026 | Dominic MarascoPres, Endocrine Business Unit | 3,623 | $4.09 | $14.8K | Form 4 | |
| Jul 15, 2026 | Stuart A TrossChief People & Workpl Officer | 93.8K | – | – | Form 4 | |
| Jul 15, 2026 | Stuart A TrossChief People & Workpl Officer | 33.7K | $4.09 | $137.6K | Form 4 | |
| Jul 15, 2026 | Stuart A TrossChief People & Workpl Officer | 8,253 | $4.09 | $33.8K | Form 4 | |
| Jul 15, 2026 | Stuart A TrossChief People & Workpl Officer | 11.6K | $4.09 | $47.3K | Form 4 | |
| Jul 15, 2026 | Stuart A TrossChief People & Workpl Officer | 12.3K | $4.09 | $50.4K | Form 4 | |
| Jul 15, 2026 | Michael CastagnaChief Executive Officer | 350.3K | – | – | Form 4 | |
| Jul 15, 2026 | Michael CastagnaChief Executive Officer | 192.8K | $4.09 | $788.6K | Form 4 | |
| Jul 15, 2026 | Michael CastagnaChief Executive Officer | 47.5K | $4.09 | $194.2K | Form 4 | |
| Jul 15, 2026 | Michael CastagnaChief Executive Officer | 64.0K | $4.09 | $261.7K | Form 4 | |
| Jul 15, 2026 | Michael CastagnaChief Executive Officer | 58.9K | $4.09 | $240.9K | Form 4 | |
| Jul 15, 2026 | Sanjay R SinghEVP Technical Operations | 70.6K | – | – | Form 4 | |
| Jul 15, 2026 | Sanjay R SinghEVP Technical Operations | 22.0K | $4.09 | $90.2K | Form 4 | |
| Jul 15, 2026 | Sanjay R SinghEVP Technical Operations | 5,372 | $4.09 | $22.0K | Form 4 | |
| Jul 15, 2026 | Sanjay R SinghEVP Technical Operations | 10.1K | $4.09 | $41.2K | Form 4 | |
| Jul 15, 2026 | Sanjay R SinghEVP Technical Operations | 9,297 | $4.09 | $38.0K | Form 4 | |
| Jul 15, 2026 | David ThomsonEVP Genl Counsel & Secretary | 10b5-1 | 93.8K | – | – | Form 4 |
| Jul 15, 2026 | David ThomsonEVP Genl Counsel & Secretary | 10b5-1 | 51.6K | $4.09 | $211.2K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jul 17, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by MNKD's officers and directors from 2005 up to November 18, 2025, 21 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 16 more, back to 2005
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
Fell to 5% or less (2)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter-56%
- Millennium Mgmt (Englander)In the quarter+113%
- Renaissance TechnologiesIn the quarter
- AQR CapitalIn the quarter-62%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | 1.22M | $4.8M | 0.01% | |
| Citadel Advisors (Griffin) | 397.2K | -56% | $1.5M | 0.00% |
| Millennium Mgmt (Englander) | 920.0K | +113% | $3.6M | 0.00% |
| Renaissance Technologies | – | – | 0.00% | |
| AQR Capital | 1.44M | -62% | $5.6M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 8.27% of its shares outstanding were held short, -2.6% since the report before.
- Shares held short
- 25.48M
- 8.27%
- Since the report before26.16M on Sep 30, 2026
- -2.6%
- 5.1
- 5.04M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 62%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 39.69M
- Nov 15, 2023: Shares held short 38.82M
- Nov 30, 2023: Shares held short 38.40M
- Dec 15, 2023: Shares held short 36.70M
- Dec 29, 2023: Shares held short 35.57M
- Jan 12, 2024: Shares held short 35.22M
- Jan 31, 2024: Shares held short 34.99M
- Feb 15, 2024: Shares held short 34.65M
- Feb 29, 2024: Shares held short 35.75M
- Mar 15, 2024: Shares held short 33.05M
- Mar 28, 2024: Shares held short 30.76M
- Apr 15, 2024: Shares held short 31.05M
- Apr 30, 2024: Shares held short 30.87M
- May 15, 2024: Shares held short 34.29M
- May 31, 2024: Shares held short 35.37M
- Jun 14, 2024: Shares held short 35.77M
- Jun 28, 2024: Shares held short 34.28M
- Jul 15, 2024: Shares held short 35.73M
- Jul 31, 2024: Shares held short 38.57M
- Aug 15, 2024: Shares held short 38.83M
- Aug 30, 2024: Shares held short 41.19M
- Sep 13, 2024: Shares held short 42.14M
- Sep 30, 2024: Shares held short 42.48M
- Oct 15, 2024: Shares held short 42.94M
- Oct 31, 2024: Shares held short 42.87M
- Nov 15, 2024: Shares held short 42.04M
- Nov 29, 2024: Shares held short 41.71M
- Dec 13, 2024: Shares held short 41.36M
- Dec 31, 2024: Shares held short 28.80M
- Jan 15, 2025: Shares held short 27.61M
- Jan 31, 2025: Shares held short 27.29M
- Feb 14, 2025: Shares held short 27.74M
- Feb 28, 2025: Shares held short 29.12M
- Mar 14, 2025: Shares held short 28.59M
- Mar 31, 2025: Shares held short 28.67M
- Apr 15, 2025: Shares held short 26.26M
- Apr 30, 2025: Shares held short 26.11M
- May 15, 2025: Shares held short 25.82M
- May 30, 2025: Shares held short 24.80M
- Jun 13, 2025: Shares held short 24.23M
- Jun 30, 2025: Shares held short 25.15M
- Jul 15, 2025: Shares held short 23.76M
- Jul 31, 2025: Shares held short 23.75M
- Aug 15, 2025: Shares held short 20.87M
- Aug 29, 2025: Shares held short 15.89M
- Sep 15, 2025: Shares held short 16.72M
- Sep 30, 2025: Shares held short 18.31M
- Oct 15, 2025: Shares held short 25.16M
- Oct 31, 2025: Shares held short 23.01M
- Nov 14, 2025: Shares held short 21.93M
- Nov 28, 2025: Shares held short 22.09M
- Dec 15, 2025: Shares held short 20.40M
- Dec 31, 2025: Shares held short 25.73M
- Jan 15, 2026: Shares held short 27.30M
- Jan 30, 2026: Shares held short 26.24M
- Feb 13, 2026: Shares held short 26.21M
- Feb 27, 2026: Shares held short 25.61M
- Mar 13, 2026: Shares held short 22.70M
- Mar 31, 2026: Shares held short 29.46M
- Apr 15, 2026: Shares held short 29.58M
- Apr 30, 2026: Shares held short 29.73M
- May 15, 2026: Shares held short 29.39M
- May 29, 2026: Shares held short 30.33M
- Jun 15, 2026: Shares held short 31.25M
- Jun 30, 2026: Shares held short 26.19M
- Jul 15, 2026: Shares held short 28.19M
- Jul 31, 2026: Shares held short 27.90M
- Aug 14, 2026: Shares held short 28.58M
- Aug 31, 2026: Shares held short 26.55M
- Sep 15, 2026: Shares held short 29.40M
- Sep 30, 2026: Shares held short 26.16M
- Oct 15, 2026: Shares held short 25.48M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading48.9% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 48.9% of the shares in the reported trades were short sales, against 47.0% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 48.9%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 47.0%
- Change
- +1.9 pts
- Short sales a dayon average, of 1.33M shares
- 651.4K
- More than atof 3,656 US-listed companies, same days
- 44%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 46.9%
- Oct 13, 2026: Short sales 44.3%
- Oct 14, 2026: Short sales 23.8%
- Oct 15, 2026: Short sales 42.6%
- Oct 16, 2026: Short sales 59.9%
- Oct 19, 2026: Short sales 52%
- Oct 20, 2026: Short sales 62%
- Oct 21, 2026: Short sales 59.2%
- Oct 22, 2026: Short sales 51.3%
- Oct 23, 2026: Short sales 72.5%
- Oct 26, 2026: Short sales 57.4%
- Oct 27, 2026: Short sales 54%
- Oct 28, 2026: Short sales 55.1%
- Oct 29, 2026: Short sales 56%
- Oct 30, 2026: Short sales 47.8%
- Nov 2, 2026: Short sales 54.5%
- Nov 3, 2026: Short sales 51.7%
- Nov 4, 2026: Short sales 46.9%
- Nov 5, 2026: Short sales 60.8%
- Nov 6, 2026: Short sales 53.8%
- Nov 9, 2026: Short sales 38.5%
- Nov 10, 2026: Short sales 42%
- Nov 11, 2026: Short sales 44.6%
- Nov 12, 2026: Short sales 41.6%
- Nov 13, 2026: Short sales 46.9%
- Nov 16, 2026: Short sales 53.9%
- Nov 17, 2026: Short sales 50.1%
- Nov 18, 2026: Short sales 39.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Michael CastagnaChief Executive OfficerDirectly2.43M
- Stuart A TrossChief People & Workpl OfficerDirectly1.06M
- David ThomsonEVP Genl Counsel & SecretaryDirectly797.6K
- Steven B. BinderDirectorDirectly713.3K
- Sanjay R SinghEVP Technical OperationsDirectly479.0K
- Dominic MarascoPres, Endocrine Business UnitDirectly343.4K
- Christopher B PrentissChief Financial OfficerDirectly318.7K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Michael CastagnaChief Executive Officer | 2.43M | – | Jul 15, 2026 | Form 4 |
| Stuart A TrossChief People & Workpl Officer | 1.06M | – | Jul 15, 2026 | Form 4 |
| David ThomsonEVP Genl Counsel & Secretary | 797.6K | – | Jul 17, 2026 | Form 4 |
| Steven B. BinderDirector | 713.3K | – | Sep 25, 2026 | Form 4 |
| Sanjay R SinghEVP Technical Operations | 479.0K | – | Jul 15, 2026 | Form 4 |
| Dominic MarascoPres, Endocrine Business Unit | 343.4K | – | Jul 15, 2026 | Form 4 |
| Christopher B PrentissChief Financial Officer | 318.7K | – | Jul 15, 2026 | Form 4 |
A lower bound: it counts only the 7 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.34%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.23%
- IBBiShares Biotechnology ETFWeight in the fund0.10%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.08%
- IWMiShares Russell 2000 ETFWeight in the fund0.04%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.04%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.03%
- VHTVanguard Health Care Index FundWeight in the fund0.02%
- VXFVanguard Extended Market Index FundWeight in the fund0.02%
- ITOTiShares Core S&P Total U.S. Stock Market ETFWeight in the fund0.00%
16 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 234
- Q4 2025: Managers 259
- Q1 2026: Managers 251
- Q2 2026: Managers 260
Institutional investors by quarter
The fund managers holding MNKD, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 260 managers held 182M shares, worth $776M. During the quarter 53 opened a position, 44 closed one, 94 added and 61 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+12%
- Rubric Capital ManagementIn the quarter+397%
- State StreetIn the quarter-13%
- Vanguard Capital ManagementIn the quarter+2.2%
- Geode Capital ManagementIn the quarter+5.9%
- Wellington Management GroupIn the quarter+139%
- Frazier Life Sciences ManagementIn the quarter+12%
- Deep Track CapitalIn the quarter
- 180 Wealth AdvisorsIn the quarter+16%
- FMRIn the quarter+18%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 32.13M | +12% | $137M |
| Rubric Capital Management | 18.00M | +397% | $77M |
| State Street | 16.17M | -13% | $69M |
| Vanguard Capital Management | 13.17M | +2.2% | $56M |
| Geode Capital Management | 7.95M | +5.9% | $34M |
| Wellington Management Group | 7.84M | +139% | $33M |
| Frazier Life Sciences Management | 6.60M | +12% | $28M |
| Deep Track Capital | 6.00M | $26M | |
| 180 Wealth Advisors | 4.96M | +16% | $21M |
| FMR | 4.10M | +18% | $17M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do MannKind's filings show?
Who buys and sells is one part of MannKind's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have MNKD's insiders bought or sold?
From Jul 17, 2026 to Sep 28, 2026 MannKind's insiders bought 0 and sold $725.6K of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold MNKD?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was AQR Capital's, worth $5.6M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.